Radioimmunoscintigraphy of ovarian tumors using a new monoclonal antibody, SM-3

Jobling, Tom; Granowska, M.; Britton, K. E.; Lowe, David; Mather, Stephen J.; Burchell, Joy; Naeem, Mahtab A.; Shepherd, John H.

doi:10.1016/0090-8258(90)90093-z

Cited by 9 publications

(6 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…SM3 was labeled with 111 In, 123 I and 99m Tc and showed a sensitivity of 95%, 100% and 100%, respectively, and an accuracy of 73%, 86% and 100%, respectively (60). However, radioimmunoscintigraphy with SM3 produced similar results to those obtained with 123 I-labeled HMFG2 (61).…”

Section: Radioimmunodetectio N Of Ovarian Cancermentioning

confidence: 76%

Radioimmunoscintigraphy in Patients with Ovarian Cancer

Kalofonos

2001

Acta Oncologica

View full text Add to dashboard Cite

The use of radiolabeled monoclonal antibodies (MoAbs) has significantly improved the ability to detect tumor antigens, thus improving in vivo tumor diagnosis and treatment. The management of ovarian carcinoma still poses a challenging medical problem. Clinical trials using radioimmunoscintigraphy or a hand-held gamma detection probe intraoperatively were performed in patients with clinical evidence of primary or recurrent ovarian cancer. Immunoscintigraphy of ovarian cancer lesions has been performed mainly with 99mTc, 111In and 123I labeled with HMFG1, HMFG2, OC-125, B72.3, H17E2, OVTL3, MoAb170, Mov18 and other MoAbs. Antibody guided imaging using radioimmunoscintigraphy has demonstrated improved targeting of ovarian cancer, resulting in a highly sensitive and specific method. However, it is not yet known which type of MoAb is the most efficient for radioimmunoscintigraphy. Since these tumors represent a potentially curable disease, radioimmunoscintigraphy could contribute mainly to accurate staging as a supplementary to conventional diagnostic methods, as well as for the localization of active disease after chemotherapy and monitoring for the presence of recurrent disease. Nevertheless, prospective studies in a large number of patients should be undertaken in order to further evaluate the diagnostic contribution of this approach.

show abstract

Section: Radioimmunodetectio N Of Ovarian Cancermentioning

confidence: 76%

Radioimmunoscintigraphy in Patients with Ovarian Cancer

Kalofonos

2001

Acta Oncologica

View full text Add to dashboard Cite

show abstract

“…However, the specificity, although the numbers are small, is much improved over 1111n-SM3, which has a specificity of 33% [20,21]. This is thought to be due to a number of factors [22,23].…”

Section: Discussionmentioning

confidence: 99%

Radioimmunoscintigraphy with technetium-99m-labelled monoclonal antibody, SM3, in gynaecological cancer

et al. 1993

Self Cite

View full text Add to dashboard Cite

Radioimmunoscintigraphy (RIS) with technetium-99m labelled SM3, a monoclonal antibody reacting with a polymorphic epithelial mucin glycoprotein core antigen, is evaluated. No adverse effects or thyroid uptake were observed. Studies in 45 patients (one twice) had a sensitivity for gynaecological malignancy of 100% (35/35) and a specificity of 73% (8/11), giving an overall accuracy of 93% (43/46). These results have led to the routine adoption of 99mTc RIS in the management of patients suspected of or having primary or recurrent gynaecological cancer.

show abstract

“…Studies with flow cytometry have shown that the monoclonal antibody SM3 has a higher specificity for ovarian carcinoma than other antibodies (Van Dam et al, 1991). This led Jobling et al (1991) and Granowska et al, 1990Granowska et al, , 1993a to use SM3-radiolabelled 99Tcm as the first choice for radioimmunoscintigraphy.…”

Section: Discussionmentioning

confidence: 99%

“…All three methods of detection may potentially be of value in the per-and immediately post-operative detection of False-positive rate (%) ovarian cancer, however a larger study comparing this with other methods of detection would be needed to confirm any clinical worth. Preoperative imaging by radioimmunoscintigraphy has been shown to be of benefit using a variety of radionuclides (Granowska et al, 1984(Granowska et al, , 1990Davies et al, 1985;Epenetos et al, 1985;Jackson et al, 1985;Critchley et al, 1986;Shepherd et al, 1987;Jobling et al, 1990) but is still not part of routine investigations for ovarian cancer in all specialist centres. Granowska et al (1993a), however, demonstrated that 99Tcm-labelled anti-PEM monoclonal antibodies produced a 100% sensitivity with a 73% specificty for ovarian cancer in external scanning.…”

Section: Discussionmentioning

confidence: 99%

“…CT scans, pelvic ultrasound and surgical exploration, even when used together, are less than 100% accurate . However, radioimmunoscintigraphy using monoclonal antibodies against polymorphic epithelial mucin and other epitopes may yield more complete preoperative information (Granowska et al, 1984(Granowska et al, , 1990(Granowska et al, , 1993Davies et al, 1985;Epenetos et al, 1985;Jackson et al, 1985; Critchley et al, 1986;Shepherd et al, 1987;Jobling et al, 1990). We decided to assess the value of peroperative radioimmunodetection (PROD) using a specially designed gamma detection probe (yDP).…”

mentioning

confidence: 99%

See 1 more Smart Citation

Peroperative radioimmunodetection of ovarian carcinoma using a hand-held gamma detection probe

Ind

Granowska²,

Britton³

et al. 1994

Br J Cancer

View full text Add to dashboard Cite

Summary Radioimmunoscintigraphy (RIS) can be used in the preoperative localisation of ovarian carcinoma to demonstrate uptake of radiolabelled monoclonal antibodies into neoplastic tissue. The tissue uptake of radiotracer was evaluated at laparotomy in 16 patients with suspected ovarian cancer who had preoperative RIS using technetium-99m-labelled monoclonal antibodies SM3 and H17E2. A gamma detection probe ('DP) was used to measure uptake in possible tumour deposits at operation and also the uptake in tissues resected for histology. The percentage uptake of the initial injected dose of radiotracer was also measured in resected tissues. Activity was found to be significantly higher in malignant than in non-neoplastic tissue by all three methods of evaluation. The yDP used peroperatively yielded a 82% sensitivity with a 72% specificity for an uptake ratio of 1.5:1. When tissue was examined immediately after resection, for a 100% specificity the sensitivity was 64%. In vitro measurements of monoclonal antibody uptake by tissue similarly gave a 65% sensitivity with a 100% specificity. Peroperative and immediate post-operative measurements of tissue radioactivity can be performed quickly and conveniently, and in some cases may be of benefit in the localisation of tumour at laparotomy and in providing extra information when tissue is examined by frozen section.Ovarian cancer has the worst prognosis of all gynaecological malignancies in the UK. It presents late and is often difficult to differentiate from benign lesions until surgery and histological examination have been performed. The surgical management of ovarian carcinoma is more complex than that of benign tumours and may be dictated by the results of histological frozen sections performed at the time of laparotomy. This is especially important in young women with unilateral ovarian tumours. In addition, a major factor determining the prognosis is whether or not there has been complete resection of the tumour. Therefore, accurate determination of the amount and extent of the tumour is essential. CT scans, pelvic ultrasound and surgical exploration, even when used together, are less than 100% accurate . However, radioimmunoscintigraphy using monoclonal antibodies against polymorphic epithelial mucin and other epitopes may yield more complete preoperative information (Granowska et al., 1984(Granowska et al., , 1990(Granowska et al., , 1993Davies et al., 1985;Epenetos et al., 1985;Jackson et al., 1985; Critchley et al., 1986;Shepherd et al., 1987;Jobling et al., 1990). We decided to assess the value of peroperative radioimmunodetection (PROD) using a specially designed gamma detection probe (yDP). We have also studied the value of measuring monoclonal antibody uptake in excised tissue as an aid to interpreting a frozen section. Patients and methodsSixteen patients having conventional routine radioimmunoscintigraphy prior to surgery for proven or suspected ovarian carcinoma were studied ( and other sites of possible involvement: Radioactivity that might come from ...

show abstract

Radioimmunoscintigraphy of ovarian tumors using a new monoclonal antibody, SM-3

Cited by 9 publications

References 6 publications

Radioimmunoscintigraphy in Patients with Ovarian Cancer

Radioimmunoscintigraphy in Patients with Ovarian Cancer

Radioimmunoscintigraphy with technetium-99m-labelled monoclonal antibody, SM3, in gynaecological cancer

Peroperative radioimmunodetection of ovarian carcinoma using a hand-held gamma detection probe

Contact Info

Product

Resources

About